Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 10/20 | 0.38 |
| ▸ | MAOA | P21397 | 10/20 | 0.38 |
| ▸ | MAOB | P27338 | 10/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7107611 | 1.00 | CHRM2 (0.40) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3827297 | 0.88 | ALDH1A1 (0.45) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3827300 | 0.88 | ALDH1A1 (0.45) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL13567837 | 0.88 | ALDH1A1 (0.45) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3831912 | 0.88 | NPSR1 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3831911 | 0.88 | NPSR1 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL13567853 | 0.88 | NPSR1 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL19707969 | 0.84 | CHRNA1 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL6980981 | 0.81 | ALDH1A1 (0.46) | — | |
| SCHEMBL6980984 | 0.81 | ALDH1A1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | disclosed |
| US-20190134005-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARM INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-20090221816-A1 | Process for the Asymmetric Epoxidation of Olefins | LANXESS DEUTSCHLAND GMBH (DE) | 2009-09-03 | — | — | US | disclosed |
| US-7544819-B2 | Process for the asymmetric epoxidation of olefins | LANXESS DEUTSCHLAND GMBH (DE) | 2009-06-09 | — | — | US | disclosed |
| CN-101208322-A | Improved synthesis of substituted 1-halomethyl-2-phenyl-1-phenyl oxirane | MAKHTESHIM CHEM WORKS LTD (IL) | 2008-06-25 | — | — | CN | disclosed |
| EP-1683791-B1 | Process for the epoxidation of olefins with hydrogen peroxide by ruthenium complex catalysed reaction | SALTIGO GMBH (DE) | 2008-04-02 | — | — | EP | disclosed |
| CN-1817871-A | Process for the ruthenium-catalyzed epoxidation of olefins with the aid of hydrogen peroxide | LANXESS DEUTSCHLAND GMBH (DE) | 2006-08-16 | — | — | CN | disclosed |
| EP-1683791-A1 | Process for the epoxidation of olefins with hydrogen peroxide by ruthenium complex catalysed reaction | Lanxess Deutschland GmbH (DE) | 2006-07-26 | — | — | EP | disclosed |
| US-20060161011-A1 | Process for the ruthenium-catalysed epoxidation of olefins by means of hydrogen peroxide | LANXESS DEUTSCHLAND GMBH (DE) | 2006-07-20 | — | — | US | disclosed |
| US-20050203303-A1 | Process for the asymmetric epoxidation of olefins | LANXESS DEUTSCHLAND GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
| EP-1021426-B1 | CATALYTIC ASYMMETRIC EPOXIDATION | UNIV COLORADO STATE RES FOUND (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6348608-B1 | ADDING OXIDIZING AGENT TO REACTION SOLUTION COMPRISING CHIRAL CYCLIC ENANTIOMERICALLY ENRICHED KETONE AND OLEFIN UNDER CONDITIONS EFFECTIVE TO GENERATE ENANTIOMERICALLY ENRICHED EPOXIDE, SEPARATING EPOXIDE FROM REACTION SOLUTION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2002-02-19 | — | — | US | disclosed |
| US-6214458-B1 | Image recording sheet comprising a white particle resin layer | FUJI PHOTO FILM CO., LTD. (JP) | 2001-04-10 | — | — | US | disclosed |
| EP-1021426-A1 | CATALYTIC ASYMMETRIC EPOXIDATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-1021426-A4 | CATALYTIC ASYMMETRIC EPOXIDATION | UNIV COLORADO STATE RES FOUND (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1998015544-A1 | CATALYTIC ASYMMETRIC EPOXIDATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1998-04-16 | — | — | WO | disclosed |
| US-4186255-A | POLYURETHANE CATALYST | TEXACO DEVELOPMENT CORPORATION (US) | 1980-01-29 | — | — | US | disclosed |
| US-4136240-A | METALLIC QUATERNARY AMMONIUM CARBOXYLATES AS POLYISOCYANURATE CATALYSTS | TEXACO DEVELOPMENT CORPORATION (US) | 1979-01-23 | — | — | US | disclosed |
| US-4075130-A | DIAMINES, TRIAMINES | TEXACO DEVELOPMENT CORPORATION (US) | 1978-02-21 | — | — | US | disclosed |
| US-4060501-A | Novolak derivatives as defoamers | TEXACO DEVELOPMENT CORPORATION (US) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203303-A1 | Process for the asymmetric epoxidation of olefins | DUOX1, DUOX2, PPOX | CHRM2 4299/4885CHRM4 3307/4885CHRM5 3862/4885 |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | CHRM2 508/4885CHRM4 306/4885CHRM5 288/4885 |
| US-20090221816-A1 | Process for the Asymmetric Epoxidation of Olefins | DUOX1, DUOX2, PPOX | CHRM2 4299/4885CHRM4 3307/4885CHRM5 3862/4885 |
| US-20060161011-A1 | Process for the ruthenium-catalysed epoxidation of olefins by means of hydrogen peroxide | PPOX, HAO2, GPX4 | CHRM2 4173/4885CHRM4 2561/4885CHRM5 3177/4885 |
| US-20190134005-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | UGCG, MAN2B1, GBA1 | CHRM2 3635/4885CHRM4 4072/4885CHRM5 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.